Abstract
In the previous chapter, we examine the limitations in the design of the 2013 DPCO. It is reasonable to expect that pharmaceutical firms likely to be affected by the regulation undertook actions to mitigate their impact. Because of such strategic actions, regulations, despite being well-intentioned, can sometimes make matters worse (Noll 1989). Have the 2013 DPCO regulations made consumers worse-off than they were before? In this chapter, we examine some of the strategies firms used to mitigate the impact of price controls. We are aware of more strategies than we discuss below. Documenting the larger set of firm strategies is part of our ongoing research agenda.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbott, T. A. (1995). Price regulation in the pharmaceutical industry: Prescription or placebo? Journal of Health Economics, 14(5), 551–565.
Alexander, J. (2013). Panel asks DoP to identify pharma cos changing compositions to dodge price control provisions. PharmaBiz [online]. Available from http://pharmabiz.com/NewsDetails.aspx?aid=77362&sid=1
Alexander, J. (2014). DoP rejects review petitions by Cipla and two other firms against price revision of scheduled drugs. PharmaBiz [online]. Available from http://pharmabiz.com/NewsDetails.aspx?aid=80890&sid=1
Armstrong, M., & Sappington, D. (2007). Recent developments in the theory of regulation. In M. Armstrong & R. Porter (Eds.), Handbook of industrial organization (Vol. 3, pp. 1557–2440). New York: North Holland.
Balakrishnan, R. (2006). Drug price gimmicks may land govt in soup. DNAIndia [online]. Available from http://www.dnaindia.com/money/report-drug-price-gimmicks-may-land-govt-in-soup-1062506
Bhaskarabhatla, A., Anurag, P., Chatterjee, C., & Pennings, E. (2018). Effort diversion as a firm strategy to respond to partial price cap regulation. Erasmus School of Economics Working Paper.
Deshpande, R. (2006). Govt may oppose price control for essential drugs. Times of India. Available from http://m.timesofindia.com/india/Govt-may-oppose-price-control-for-essential-drugs/amp_articleshow/1682614.cms.
Dubashi, J. (1985, October 31). Opposition to druggists’ doyen from within trade ranks grows. India Today.
Ellison, S.-F., & Wolfram, C. (2006). Coordinating on lower prices: Pharmaceutical pricing under political pressure. RAND Journal of Economics, 37(2), 324–340.
Ghangurde, A. (1998, July 27). Burroughs wellcome changes actifed content; gets it off DPCO. Indian Express. Available from http://expressindia.indianexpress.com/fe/daily/19980728/20955804p.html
Glazer, A., & McMillan, H. (1992). Pricing by the firm under regulatory threat. Quarterly Journal of Economics, 107(August), 1089–1099.
Gopakumar, K. (2017, May 19). Drug price control: For cheaper medicines, we need a cost-based formula for caps. Financial Express.
Gulhati, C. M. (2004). Why drug price regulation. PharmaBiz [online]. Available from http://pharmabiz.com/ArticleDetails.aspx?aid=24980&sid=21
Malhotra, P. (2010). The Impact of TRIPS on India: An access to medicines perspective. UK: Palgrave Macmillan.
Mathew, J. C. (2005). Industry unhappy over reference price plans. PharmaBiz [online]. Available from http://pharmabiz.com/NewsDetails.aspx?aid=28314&sid=2
Mathew, J. C. (2006). Technical approach to NLEM in new pharma policy may benefit drug industry. PharmaBiz [online]. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=33202&sid=2
Mukherjee, R. (2006). Pharma players to meet Paswan on pricing. Times of India [online]. Available from http://timesofindia.indiatimes.com/business/india-business/Pharma-players-to-meet-Paswan-on-pricing/articleshow/1398672.cms
Nagappa, A. N., Sharma, R., and Bokolia, R. (2015). Drug pricing reforms in changing times. PharmaBiz [online]. Available from http://pharmabiz.com/NewsDetails.aspx?aid=89310&sid=9
Nautiyal, S. (2014). State FDA to approach NPPA for overcharging Crocin drops. PharmaBiz [online]. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=81485&sid=1
Noll, R. G. (1989). The politics of regulation. In R. Schmalensee & R. Willig (Eds.), Handbook of industrial organization. New York: North Holland.
Pant, S., Sah, A. K., & Khurana, A. K. (2016). Report of the committee on high trade margins in sale of drugs. Department of Pharmaceuticals, Government of India. Available from https://ideas.repec.org/p/ess/wpaper/id10219.html
PharmaBiz.com. (2017, May 18). Drug regulator serves notices to pharma cos for violating pricing norms for combination drugs. PharmaBiz.com. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=102018&sid=2
PharmaQuest (2009). Paswan blames powerful industry lobby for thwarting national pharma policy. PharmaQuest [online]. Available from http://www.pharmaquest.biz/paswan-blames-powerful-industry-lobby-for-thwarting-national-pharma-policy/
Pradhan, R. (2011, November 25). New drug pricing policy may increase prices of essential medicines. Moneylife.in [online] Available from https://www.moneylife.in/article/new-drug-pricing-policy-may-increase-prices-of-essential-medicines/21707.html
Ray, T. J. (2013). New drug price control order of India: Is it directionally right improving access to medicines? [online]. Available from http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/
Rana, S. (2015). IDMA urges govt not to cap trade margin as it may affect availability of generic drugs in rural areas. PharmaBiz [online]. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=91838&sid=1
Rana, S. (2016). AIOCD vehemently opposes govt move to cap trade margin of retailers & wholesalers. PharmaBiz [online]. Available from http://pharmabiz.com/NewsDetails.aspx?aid=92776&sid=1
Shankar, R. (2014a). NPPA rejects demand to keep differentiated/modified dosage forms out of DPCO 2013. PharmaBiz [online]. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=85885&sid=1
Shankar, R. (2014b). FICCI seeks health minister's intervention to sort out issues arising out of implementation of DPCO 2013. PharmaBiz [online]. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=82467&sid=1
Shankar, R. (2017). Sun Pharma gets positive verdict from DoP on revision of ceiling price of nitrofurantoin capsule. PharmaBiz [online]. Available from http://pharmabiz.com/PrintArticle.aspx?aid=100994&sid=1
The Sen Committee. (2005). Report: Task force to explore options other than price control for achieving the objective of making available life-saving drugs at reasonable prices. New Delhi: Department of Chemicals and Petrochemicals, Government of India.
Unnikrishnan, C. H. (2012a). Market-based drug pricing formula gets GoM nod. Live Mint [online]. Available from http://www.livemint.com/Politics/9VC3FPESRKUFRyxHXMvgOJ/GoM-pitches-for-marketbased-system-for-drug-price-control.html
Unnikrishnan, C. H. (2012b). New drug pricing policy may hit profitability of firms. Live Mint [online]. Available from http://www.livemint.com/Industry/thYjee2K9jiIVshL6zQZ0O/New-drug-pricing-policy-may-hit-profitability-of-firms.html
Singh, C. U. (1984, January 15). Bombay retailers demand raise in margins by manufacturers, threaten series of boycotts. India Today. Available from https://www.indiatoday.in/magazine/economy/story/19840115-bombay-retailers-demand-raise-in-margins-by-manufacturers-threaten-series-of-boycotts-803574-1984-01-15
The Financial Express. (2005). Hows & whys of drug price control. The Financial Express [online]. Available from http://www.financialexpress.com/archive/hows-whys-of-drug-price-control/147672/
The Hindu Business Line (2007). Pharma industry opposes price control mechanism. The Hindu Business Line [online]. Available from http://www.thehindubusinessline.com/todays-paper/pharma-industry-opposes-price-control-mechanism/article1646222.ece
Vijay, N. (2015a). Govt should define role of wholesalers in DPCO 2013, frame norms for drug substitution: AIOCD. PharmaBiz [online]. Available from http://pharmabiz.com/NewsDetails.aspx?aid=89480&sid=1
Vijay, N. (2015b). BDCDA urges DoP to facilitate regulations to raise trade margins of wholesalers & retailers to 10% & 20% respectively. PharmaBiz [online]. Available from http://pharmabiz.com/NewsDetails.aspx?aid=90178&sid=1
Vijay, N. (2016). Price control on coronary stents necessitates margin regulations across value chain: Kaustav Ganguli. PharmaBiz [online]. Available from http://pharmabiz.com/NewsDetails.aspx?aid=96773&sid=1
Yadav, L. (2016). AIOCD demands capping trade margin on drugs at 50%. PharmaBiz [online]. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=94038&sid=1
Yadav, L. (2017a). AIOCD to go on day-long nationwide token strike in April. PharmaBiz [online]. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=100565&sid=1
Yadav, L. (2017b). AIOCD demands changes in DPCO provisions to ensure availability, affordability of drugs. PharmaBiz [online]. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=101734&sid=1
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Bhaskarabhatla, A. (2018). Firm Strategies to Mitigate the Impact of Price Control Regulation. In: Regulating Pharmaceutical Prices in India. India Studies in Business and Economics. Springer, Cham. https://doi.org/10.1007/978-3-319-93393-1_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-93393-1_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-93392-4
Online ISBN: 978-3-319-93393-1
eBook Packages: Economics and FinanceEconomics and Finance (R0)